Aribio completes global Phase 3 trial for oral Alzheimer's drug, to unveil top-line data Monday

Aribio has completed the main Phase 3 trial of AR1001, its oral Alzheimer's disease treatment candidate, and is set to release final efficacy data in the coming days.

The milestone is drawing attention as a rare case of a Korean pharmaceutical and biotech company completing a multinational Phase 3 trial while retaining full operational control, rather than relying solely on external technology transfers.

According to industry sources, Aribio will present the top-line results of the AR1001 global Phase 3 trial at the Clinical Trials on Alzheimer's Disease conference (CTAD 2026) in Boston on Monday.

AR1001 is an oral synthetic drug candidate designed for once-daily use in patients with early-stage Alzheimer's disease. It targets mechanisms that protect brain neurons and slow disease progression, and if commercialized, is expected to significantly improve patient convenience compared with existing injection-based treatments.

The global Phase 3 trial enrolled 1,535 early-stage Alzheimer's patients across 13 countries, including the United States, European nations, South Korea and China.

The trial compared AR1001 and placebo groups over 52 weeks. Of the enrolled patients, 1,348 — or 87.8 percent — completed the full 52-week dosing period.

The last patient completed dosing on June 29, and 95.5 percent of those who finished the main trial have since enrolled in an extension study evaluating long-term safety.

Aribio oversaw every stage of the trial through its US-based clinical operations team, from protocol design to management of trial sites and contract research organizations across participating countries. The company also raised more than 150 billion won ($112 million) through regional licensing agreements and other arrangements to self-fund the large-scale Phase 3 costs.

Under a global licensing option agreement with China's Fosun Pharma, Aribio received $60 million. Last month, the first tranche of a separate equity investment — about 11.5 billion won — was also paid in, translating the commercialization partnership into tangible cash inflows.

The primary focus at Monday's CTAD presentation will be the trial's main efficacy endpoint: whether AR1001 meaningfully slowed the decline of memory, judgment and daily functioning compared with placebo, and whether the results achieved statistical significance. Long-term safety data from extended dosing are also expected to be a key factor in regulatory approval decisions.